ArticleOncoTargets and therapy2017
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 41 citations in OpenAlex.
- Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.Antibodies (Basel, Switzerland) · 2024Article
- Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1.Cancers · 2023Article
- Article
- The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Facile Fabrication of Methyl Gallate Encapsulated Folate ZIF-L Nanoframeworks as a pH Responsive Drug Delivery System for Anti-Biofilm and Anticancer Therapy.Biomimetics (Basel, Switzerland) · 2022Article
- Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.Molecular biology reports · 2022Review
- ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.Neuro-oncology · 2022Article
- Role of immune escape in different digestive tumours.World journal of clinical cases · 2021Review
- Advances and challenges in the treatment of esophageal cancer.Acta pharmaceutica Sinica. B · 2021Review
- Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.Current treatment options in oncology · 2021Review
- Review
- PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.Cell reports · 2021Article
- Circular RNA AKT3 governs malignant behaviors of esophageal cancer cells by sponging miR-17-5p.World journal of gastroenterology · 2021Article
- Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway.Frontiers in oncology · 2021Article
- The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.Cancer communications (London, England) · 2021Article
- Time series expression pattern of key genes reveals the molecular process of esophageal cancer.Bioscience reports · 2020Article
- TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.Nature cell biology · 2019Article
- Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.Journal of hematology & oncology · 2019Review
- Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.Molecular cancer · 2019Review
- Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.Clinical and experimental hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the potential effect of activation of epidermal growth factor receptor (EGFR) signaling pathway on the expression of programmed death-ligand 1 (PD-L1) in esophageal squamous cell carcinoma (ESCC) cells with EGFR overexpression.
methodsFlow cytometry and Western blot methods were used to assess PD-L1 expression on ESCC cells when EGFR signaling pathway was activated by epidermal growth factor (EGF) with or without EGFR-specific inhibitor AG-1478, and then EGFR signaling array was applied to analyze the potential signaling pathways involved.
resultsThis study found that PD-L1 expression increased significantly in an EGFR-dependent manner by the activation of EGFR signaling and decreased sharply when EGFR signaling was blocked. The upregulated expression of PD-L1 was not associated with EGFR-STAT3 signaling pathway, but may be affected by EGFR-PI3K-AKT, EGFR-Ras-Raf-Erk, and EGR-PLC-γ signaling pathways.
conclusionThe expression of PD-L1 can be regulated by EGFR signaling activation in ESCC, which indicates an important role for EGFR-mediated immune escape and potential molecular pathways for EGFR-targeted therapy and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.